June 3, 2021 11:46 AM EDTUpdated 12:10 PM

#ASCO21: Novartis flashes 'groundbreaking data' for $2B radioligand drug

Jason Mast

Editor

Here’s the “groundbreaking” data from the prostate cancer drug Novartis spent $2 billion to acquire: The molecule hit every endpoint in the Phase III trial …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ASCO21: Novartis flashes 'groundbreaking data' for $2B radioligand drug

Jason Mast

Editor

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

New fund will pressure flailing biotechs, as investor frustration boils over

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

#AS­CO21: No­var­tis flash­es 'ground­break­ing data' for $2B ra­di­oli­gand drug

Editor

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

#ASCO21: Novartis flashes 'groundbreaking data' for $2B radioligand drug